Centers For Medicare And Medicaid Services Has Reassigned CVRx's Barostim Implant Procedure For Procedures Performed In The Outpatient Setting As Part Of The 2024 Medicare Hospital Outpatient Prospective Payment System Final Rule
Portfolio Pulse from Benzinga Newsdesk
The Centers for Medicare and Medicaid Services has reassigned CVRx's Barostim Implant Procedure for procedures performed in the outpatient setting as part of the 2024 Medicare Hospital Outpatient Prospective Payment System Final Rule. CVRx is focused on the development and commercialization of the Barostim™ System, a FDA-approved medical technology that uses neuromodulation to improve the symptoms of heart failure.
November 03, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CVRx's Barostim Implant Procedure has been reassigned for procedures performed in the outpatient setting by the Centers for Medicare and Medicaid Services. This could potentially increase the accessibility and usage of the procedure, positively impacting CVRx.
The reassignment of CVRx's Barostim Implant Procedure for procedures performed in the outpatient setting could potentially increase the accessibility and usage of the procedure. This could lead to an increase in revenues for CVRx, positively impacting its stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100